Why is Concord Biotech falling/rising?

As of 24-Jun, Concord Biotech Ltd is experiencing a decline in its stock price, currently at Rs 1,771.10, which reflects a decrease of Rs 51.4 or 2.82%. The stock has been underperforming, having fallen consecutively for the last seven days, resulting in a total decline of 16.26% during this period. Today's trading saw the stock touch an intraday low of Rs 1,764.3, and it has been trading with lower volumes, as evidenced by a 37.9% drop in delivery volume compared to the five-day average. Despite a strong long-term fundamental outlook, including a healthy return on equity and significant growth in operating profit, the recent performance has been negatively impacted by falling investor participation and a decline in stock price.
In the broader market context, Concord Biotech's short-term performance has been significantly worse than the benchmark, with a one-week return of -13.90% compared to the Sensex's gain of 0.58%. While the stock has shown positive returns over the past year, outperforming the market with a 16.42% increase against a 6.10% rise in the Sensex, the recent downturn indicates a shift in investor sentiment. The increasing participation of institutional investors, who have raised their stake in the company, suggests potential long-term confidence; however, this has not yet translated into short-term price stability, highlighting a disconnect between long-term fundamentals and current market performance.